XERS Stock Analysis: Buy, Sell, or Hold?
XERS - Xeris Biopharma Holdings, Inc. Common Stock
$6.38
-0.05 (-0.78%)
▼
5d:
-3.77%
30d:
+2.9%
90d:
-7.67%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
XERS is down 3.8% this week, but smart money is accumulating calls. Top strike: $7.5 2026-07-17 with 4,088 OI. Call ratio: 63% View Scanner →
Strength: 3.2/10
Get Alerted When XERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called XERS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XERS shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: XERS shows positive signals but monitor for confirmation. Market pricing in 0.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$12.70
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$7.89
19.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XERS is currently trading at $6.38, which is considered extended relative to its 30-day fair value range of $5.96 to $6.35. The stock's valuation (Forward PE: 18.9) is in line with its historical norms (19.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, XERS is in a strong downtrend. Immediate support is located at $6.10, while resistance sits at $7.00.
Market Sentiment: XERS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+76.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XERS is in a strong downtrend. Immediate support is located at $6.10, while resistance sits at $7.00.
Market Sentiment: XERS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.29 (+76.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.96 -
$6.35
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 76.9% below Wall St target ($11.29)
Trading Range Analysis
30-Day Trading Range
$5.96 -
$6.35
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.10
Resistance Level
$7.01
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.88
Wall Street Target
$11.29
(+76.9%)
Revenue Growth (YoY)
38.3%
Profit Margin
3.8%
Valuation Discount vs History
-0.7% cheaper
PE vs Historical
18.9 vs 19.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.7%
(market-implied from PE analysis)
1-Year Target
$6.34
(-1%)
2-Year Target
$6.29
(-1%)
3-Year Target
$6.25
(-2%)
3-Yr Target (if PE normalizes)
(PE: 19→19)
$6.39
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 198.3%)
$25.14
(+294%)
Base:
(SPY PE: 18.9, Growth: 198.3%)
$21.53
(+238%)
Bear:
(PE: 16.0, Growth: 198.3%)
$18.30
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (92x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 91.86 | Current EPS (TTM): $0.07
Bull Case
$14.15
(+122%)
Analyst growth 100.0%, PE expands to 101.0
Base Case
$12.86
(+102%)
Market implied 100.0%, PE stable at 91.9
Bear Case
$4.37
(-32%)
Severe decline -20.0%, PE contracts to 78.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.9 to 19.3
Stabilization Target:
$6.52
(+2.2%)
PE Expansion Potential:
+2.2%
Share & Embed Analysis
Last updated: May 14, 2026 9:47 PM ET
Data refreshes hourly during market hours. Next update: 10:47 PM
Data refreshes hourly during market hours. Next update: 10:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Beth Hecht
SELL
16667 shares
2026-04-01
James Aloysius Brady
SELL
10834 shares
2026-03-30
Beth Hecht
SELL
16667 shares
2026-03-02
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |